EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Elicera Therapeutics AB (ELIC) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Elicera Therapeutics AB SEK 0.30, price SEK 2.74, upside -89.1%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE · ISIN SE0015382080

ET Thin data Sep 24, 2026

Elicera Therapeutics AB

ELIC · ST

Weakest SetupStrongly overvalued and low quality.

!Fair value kr 0.2975 · Strongly overvalued (−89%)
!Quality 43/100
!Mixed Growth (revenue 3y +2198.5 %/yr)
!Loss-making · -135.9% net margin (TTM)
!negative free cash flow
!Trails peers (3/9)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
Watch Elicera Therapeutics AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 8.56 kr 0.8520 Fair Value kr 0.2975 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range kr 0.8520 – kr 8.56 · fair‑value band kr 0.1955 – kr 0.3740 · the kr 2.74 price screens above the kr 0.2975 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Elicera Therapeutics in your weekly email

Every Wednesday you see whether Elicera Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden.

Show more

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.

Stock analysis

Elicera Therapeutics AB (ELIC) currently trades at kr 2.74, while our model-based Fair Value estimate is kr 0.2975, implying the stock looks roughly 819.1% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: kr 0.1955 (bear) to kr 0.3740 (bull), the price of kr 2.74 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Elicera Therapeutics AB reported revenue of 0 SEK in FY2025 versus 587 SEK in FY2021. Reported net income was −17.4M SEK in FY2025.

Key figures

Market cap 178M SEK (≈ $18.0M) · P/S ratio 16.8 · EPS (TTM) kr −0.2500 · Net margin −136% · Return on equity −56.6% · Return on assets (EBIT) −57.3% · Operating margin −141% · Revenue (TTM) 10.6M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).

What moves the price

The share trades about 65% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −89%, ELIC screens richer than that median.

Fair Value models

Bear kr 0.1955 Fair Value kr 0.2975 Bull kr 0.3740
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 0.1800 kr 0.2300 kr 0.3500 51
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.1800 kr 0.2300 kr 0.3500 51

Open the full fair value analysis →

Notify me when ELIC reaches fair value

Put ELIC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 49 · Market factors (momentum, volatility) 25

Profitability 12
Margins and returns on capital today
Quality Growth 0
Are margins and returns improving?
Cashflow 75
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 20
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 25/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−36.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2,198.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,234,986.0% (2021) → −236.9% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ELIC screens 819% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Elicera Therapeutics AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 49 · Above median
Fair Value upside −89% · Bottom 25%
Profitability
Return on assets −28% · Below median
Net margin (TTM) −136% · Bottom 25%
Operating margin (TTM) −141% · Bottom 25%
Growth and dividend
Revenue growth −99% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.77× · Cheaper than median
P/S (TTM) 1.69× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Elicera Therapeutics AB · Fair Value
kr 0.2975 −819%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Elicera Therapeutics AB Fair Value". https://www.fairvalue-calculator.com/stock/ELIC

Frequently asked questions

Is Elicera Therapeutics AB (ELIC) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 0.2975 versus a price of kr 2.74, about −89% upside (overvalued).
What is the fair value of ELIC?
Our model-based fair value for Elicera Therapeutics AB is kr 0.2975 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 2.74.
What is the quality score of ELIC?
Elicera Therapeutics AB has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Elicera Therapeutics AB (ELIC)?
Our model-based price target is the fair value of kr 0.2975 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 0.1955, optimistic scenario kr 0.3740. It is a calculation from audited fundamentals, not an analyst target.
What is the Elicera Therapeutics AB stock forecast for 2026?
Our models put fair value at kr 0.2975, about −89% upside versus a price of kr 2.74 (overvalued). Cautious scenario kr 0.1955, optimistic scenario kr 0.3740. The calculation is refreshed regularly with new filings.
What is the revenue of Elicera Therapeutics AB (ELIC)?
Elicera Therapeutics AB reported trailing-twelve-month revenue of about 10.6M SEK (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Elicera Therapeutics AB (ELIC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Elicera Therapeutics AB it is kr 0.2975 per share (as of Sep 24, 2026), against a price of kr 2.74. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Elicera Therapeutics AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ELIC trades above its calculated fair value: price kr 2.74, fair value kr 0.2975, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ELIC?
No. The price is what the market pays today (kr 2.74); the fair value is what the company's own numbers justify (kr 0.2975). For Elicera Therapeutics AB the two are kr 2.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is Elicera Therapeutics AB worth?
The market values Elicera Therapeutics AB at about 178M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 2.74; our models calculate a fair value of kr 0.2975 per share.
What do the bullish and bearish scenarios say about ELIC?
Our models span a range for Elicera Therapeutics AB: cautious scenario kr 0.1955, base kr 0.2975, optimistic kr 0.3740 per share (as of Sep 24, 2026, price kr 2.74). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Elicera Therapeutics AB (ELIC)?
Balance-sheet figures for Elicera Therapeutics AB (as of Sep 24, 2026): return on equity −56.6%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is ELIC from its 52-week high?
Elicera Therapeutics AB trades at kr 2.74, about 65% below its 52-week high of kr 7.90 and 19% above the low of kr 2.30 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.2975 is for.
Which stocks are comparable to Elicera Therapeutics AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Elicera Therapeutics AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 2.74, calculated fair value kr 0.2975 (−89%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ELIC calculated?
We run Elicera Therapeutics AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.2975, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Elicera Therapeutics AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Elicera Therapeutics AB (ELIC)?
The closing price on Sep 24, 2026 was kr 2.74. Our model-based fair value is kr 0.2975, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Elicera Therapeutics AB right now?
The price sits above even our optimistic bull case (kr 0.3740). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.1955 to kr 0.3740) leaves room in how you read the outcome.

Key figures of Elicera Therapeutics AB

How large is the market capitalisation of Elicera Therapeutics AB (ELIC)?
The market capitalisation of Elicera Therapeutics AB is 178M SEK (≈ $18.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Elicera Therapeutics AB (ELIC)?
The price-to-sales ratio of Elicera Therapeutics AB is 16.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Elicera Therapeutics AB (ELIC)?
Earnings per share at Elicera Therapeutics AB are kr −0.2500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Elicera Therapeutics AB (ELIC)?
The net margin of Elicera Therapeutics AB is −136% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Elicera Therapeutics AB (ELIC)?
The return on equity (ROE) of Elicera Therapeutics AB is −56.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Elicera Therapeutics AB (ELIC)?
On an EBIT basis the return on assets of Elicera Therapeutics AB is −57.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Elicera Therapeutics AB (ELIC)?
The operating margin of Elicera Therapeutics AB is −141% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Elicera Therapeutics AB (ELIC)?
Revenue at Elicera Therapeutics AB is growing −99.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Elicera Therapeutics AB (ELIC) generate?
The free cash flow of Elicera Therapeutics AB is −21.6M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Elicera Therapeutics AB (ELIC) hold?
Elicera Therapeutics AB holds more cash than debt, 24.8M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Elicera Therapeutics AB in the live analysis

One click puts Elicera Therapeutics AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.